With options, Missling has more stock than any single institution or shareholder.
Believe me, he is fully invested and has been for years.
Missling and SAVA CEO both own around 8%.
Your point is moot...
I don't know much about SAVA's competing drug to A-273, but I can tell that SAVA has a significantly better CEO who is willing to make a large insider purchase -- something Missling has yet to do on a regular basis.